uMotif, a data capture firm working in the healthcare space, has raised £2.4m in a round led by Albion Capital.

The firm, has created a software platform provides patient-facing technology to capture data for clinical research initiatives, also raised from several Angel investors.

uMotif says its technology is already being used by some pharmaceutical companies – including AstraZeneca and Novartis – in Europe and North America.

Andrew Elder, partner at Albion Capital, spoke about the investment: “uMotif has developed a game-changing product for the health and pharma industries, opening new doors to creating more successful treatments, enabled through unprecedented patient engagement. Since launching five years ago, Bruce and Ben have done a fantastic job in positioning uMotif as one of the world leaders in a field which is notoriously hard to penetrate with new technology.

“We are hugely excited about the growth potential of the company moving forward and, as the first institutional investor to come aboard, we look forward to working with the team to fulfil their expansion strategy.”

Launched in approximately six years ago by Bruce Hellman and Ben James, the startup will use the cash to scaleup its team and continue developing the product.

Hellman, also the CEO, said he was delighted to have secured the funding.

“We see this investment as adding rocket fuel to fire that’s already burning brightly. It will enable us to bring on even more world class talent and remain at the forefront of patient-centric technology,” he added.